AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01909713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Facial Cleanser and Moisturizer SPF 30
Description: Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
Study NCT03066544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Nerve blocks with bupivacaine will be performed at initial visit
Study NCT02522260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance and aerobic training
Description: Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
Study NCT02522260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
Study NCT02522260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: Standard supportive care
Study NCT03508570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given i.p.
Study NCT03508570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03614715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1A
Description: A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
Study NCT03508570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given i.p.
Study NCT03508570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03614715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
Study NCT00098345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: oral once daily tablet
Study NCT04649281 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometry
Description: Recording of sleep and physical activity by accelerometry during one week.
Study NCT03015272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory-Motor Mapping Training
Description: AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
Study NCT03015272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-Repetition Therapy
Description: SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
Study NCT00950781 — intervention group
Intervention type: PROCEDURE
Intervention: ACTH
Description: During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
Study NCT00929578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluphenazine
Description: Intralesional injection of Fluphenazine
Study NCT00929578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intralesional injection of placebo
Study NCT03066544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naratriptan Pill
Description: one pill will be administered twice each day for 5 days
Study NCT03066544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: one tablet will be administered twice each day for 3 days
Study NCT03066544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
Study NCT01218360 — intervention group
Intervention type: DRUG
Intervention: Physician standard-of-care
Description: Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
Study NCT01196390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01196390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01196390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01196390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01196390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01196390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01196390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT01063712 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nit-Occlud® PDA-R
Description: Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure.
Study NCT00891111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Payment
Description: $25 gift card given upon completion of Health Risk Assessment
Study NCT00891111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret Lottery
Description: Entered into a lottery upon completion of Health Risk Assessment
Study NCT01507454 — intervention group
Intervention type: DRUG
Intervention: estradiol, 25 mcg
Description: Vaginal tablets for 6-12 weeks according to product labelling
Study NCT00997438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic Acid
Description: 300 mg Lipoic acid tablets from Vital Nutrients
Study NCT01236118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously
Study NCT03396393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin tablet
Description: DHA tablet
Study NCT01123447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and internal fixation
Description: Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
Study NCT01123447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed reduction and short-arm cast
Description: Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
Study NCT00143273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: 0.05 mg tablets
Study NCT00143273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg
Study NCT00143273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: 0.25 mg tablets
Study NCT00143273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: 0.5 mg tablets
Study NCT00857779 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunotherapy
Description: 7 injections
Study NCT04125407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor foot orthoses
Description: The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, ...) focusing on the flatfoot deformity.
Study NCT03787004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6970
Description: Oral dose CNTX-6970
Study NCT03979794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention for Wellness and Engaged Living (Be-WEL)
Description: Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
Study NCT00252564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg over 30 minutes on Days 1 and 15
Study NCT00252564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 on Days 1 and 15
Study NCT00252564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 on Days 1 and 15
Study NCT00252564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
Study NCT00252564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
Study NCT01539564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl Microspheres
Study NCT01936662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA
Description: Patients randomized to the LMA group had their airways maintained with a LMA device
Study NCT01936662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETT
Description: Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
Study NCT01327976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vBloc (Active Device)
Description: Active device will deliver vBloc Therapy
Study NCT01327976 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (Non-active Device)
Description: Functional non-active control device will deliver no vBloc Therapy
Study NCT00414479 — intervention group
Intervention type: DRUG
Intervention: praziquantl, iron, ACT
Study NCT02588911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
Study NCT02588911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Catheter-based ablation of the great saphenous vein
Study NCT02772822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT400 plus CHOP
Study NCT02772822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab plus CHOP
Study NCT01957280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patritumab
Study NCT00796913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop medication
Description: Stop medication Stop medication + se supplement
Study NCT00796913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stop medication
Description: Stop medication Stop medication + se supplement
Study NCT02663661 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Metabolic Challenge Admission
Description: A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
Study NCT02663661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CGM home test
Description: A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
Study NCT04605835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.
Description: The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
Study NCT01531816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation intervention
Description: 1. Passive mobility: cycle ergometer~2. Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention.
Study NCT02694536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
Study NCT02694536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
Study NCT02396888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Half of the wound surface was treated daily with 10 units of intermediate insulin.
Study NCT03787004 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose placebo
Study NCT04503551 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.
Study NCT04503551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.
Study NCT04503551 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Ranibizumab 0.5 mg Injection
Description: Will be administered as per the schedule described in individual arm.
Study NCT04503551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab 0.5 mg Injection
Description: Will be administered as per the schedule described in individual arm.
Study NCT03867500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)
Study NCT03867500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous infusion of 0.9% Sodium chloride (NaCl)
Study NCT01823796 — intervention group
Intervention type: OTHER
Intervention: Fibromyalgia women group
Description: Assessment of this group at baseline in order to be compared with a control group.
Study NCT01823796 — intervention group
Intervention type: OTHER
Intervention: Healthy women
Description: These women are assessed in order to be compared with fibromyalgia women group.
Study NCT04050007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive initiation of fluid removal
Description: Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines
Study NCT04050007 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Curative initiation of fluid removal
Description: The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines
Study NCT02039271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
Study NCT00312780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL784
Description: XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
Study NCT00312780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XL784
Description: XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
Study NCT00849303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait-oriented rehabilitation
Description: Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
Study NCT00849303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait-oriented rehabilitation
Description: Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
Study NCT01025778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine for remission induction
Study NCT01025778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide for remission induction
Study NCT01025778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for remission induction
Study NCT01025778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine in conditioning before transplantation
Study NCT01025778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa in conditioning before transplantation
Study NCT01025778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melfalan in conditioning before transplantation
Study NCT01025778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical transplantation of T-cell depleted graft
Study NCT01025778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion
Study NCT01971879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff.
Study NCT01971879 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff.